Beyond a chemopreventive reagent, aspirin is a master regulator of the hallmarks of cancer

J Cancer Res Clin Oncol. 2019 Jun;145(6):1387-1403. doi: 10.1007/s00432-019-02902-6. Epub 2019 Apr 29.

Abstract

Purpose: Aspirin, one of the most commonly used nonsteroidal anti-inflammatory drugs (NAIDS), not only shows cancer chemoprevention effects but also improves cancer therapeutic effects when combined with other therapies. Studies that focus on aspirin regulation of the hallmarks of cancer and the associated molecular mechanisms facilitate a more thorough understanding of aspirin in mediating chemoprevention and may supply additional information for the development of novel cancer therapeutic agents.

Methods: The relevant literatures from PubMed have been reviewed in this article.

Results: Current studies have revealed that aspirin regulates almost all the hallmarks of cancer. Within tumor tissue, aspirin suppresses the bioactivities of cancer cells themselves and deteriorates the tumor microenvironment that supports cancer progression. In addition to tumor tissues, blocking of platelet activation also contributes to the ability of aspirin to inhibit cancer progression. In terms of the molecular mechanism, aspirin targets oncogenes and cancer-related signaling pathways and activates certain tumor suppressors.

Conclusion: Beyond a chemopreventive agent, aspirin is a master regulator of the hallmarks of cancer.

Keywords: Aspirin; Cancer; Cancer therapy; Hallmark of cancers.

Publication types

  • Review

MeSH terms

  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology
  • Anticarcinogenic Agents
  • Aspirin / pharmacology*
  • Energy Metabolism
  • Humans
  • Neoplasms / drug therapy*
  • Neoplasms / metabolism
  • Neoplasms / pathology
  • Neoplasms / prevention & control
  • Platelet Activation / drug effects
  • Tumor Microenvironment / drug effects

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Anticarcinogenic Agents
  • Aspirin